Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

NCT01276769 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Triple Negative Breast Cancer

Interventions

DRUG: Paclitaxel plus carboplatin
DRUG: Paclitaxel and epirubicin

Sponsor

Chinese Academy of Medical Sciences